Inspections, Compliance, Enforcement, and Criminal Investigations
Department of Health and Human Services
|Public Health Service
Food and Drug Administration
|Silver Spring, MD 20903|
From: FDA Center for Drug Evaluation and Research
Date: November 16, 2009
TO: William Wynne
UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MD 20903
TO: William Wynne
FROM: Food and Drug Administration Internet Pharmacy Task Force
RE: Internet Marketing of Unapproved and Misbranded Drugs
DATE: November 16, 2009
The United States Food and Drug Administration (FDA) has reviewed your websites at
andersenpharmacy.com and dukepharmacy.com and has determined that you are offering
products for sale in violation of the Federal Food, Drug, and Cosmetic Act (the Act). These
products include, but are not limited to "Acomplia (Brand)," "Acomplia (Generic) "Rimonabant,"
"Herbal Ambien," "Herbal Xanax," "Valium (Brand)," "Valium (Generic)," and "Prozac (Generic)."
We request that you immediately cease marketing violative products.
These products are drugs under section 201 (g) of the Act, 21 U.S.C. § 321 (g), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. Your marketing and distribution of these drugs violate various provisions of the Act, as described below:
Unapproved New Drugs
Your firm offers many unapproved new drugs including, but not limited to "Acomplia (Brand),"
"Acomplia (Generic)," "Rimonabant," "Herbal Ambien," and "Herbal Xanax." FDA is taking this
action against your firm because of the inherent risk in buying unapproved prescription drugs.
Unapproved drugs from unregulated sources do not have the same assurance of safety and
effectiveness as drugs subject to FDA oversight and have been found to be contaminated,
counterfeit, contain varying amounts of active ingredients, or contain different ingredients
altogether. For drugs that are regulated by FDA, FDA protections include rigorous scientific
standards for prescription drug approval and label review for accuracy and completeness,
manufacturing procedures and testing performed under closely controlled conditions at FDA registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public from unregulated sources may not be safe and effective.
Rimonabant (also marketed under the name Acomplia) was specifically rejected for FDA approval
because it did not meet the statutory requirements for safety and effectiveness. In June 2007,
the FDA Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted not to
recommend approval of the drug because of increased risk of neurological and psychiatric side
effects including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts
among patients. Accordingly, the "Acomplia (Brand)," "Acomplia (Generic)," and "Rimonabant"
dispensed through your websites are "new drugs," as defined by section 201 (p) of the Act, 21
U.S.C. § 321 (p).
You also offer "Herbal Ambien," and "Herbal Xanax," on your websites. Ambien and Xanax are
approved drugs well-known for their intended use(s) to treat disease. Therefore, including these
drug names causes "Herbal Ambien" and "Herbal Xanax" to be subject to regulation as drugs
under Section 201 (g) of the Act because they are intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease. Moreover, these products are new drugs, as
defined by section 201 (p) of the Act, 21 U.S.C. § 321 (p).
Under sections 301 (d) and 505(a) of the Act, 21 U.S.C. §§ 331 (d) and 355(a), a new drug may
not be introduced or delivered for introduction into interstate commerce unless an FDA-approved
application is in effect for it. Your sale of several products, including "Acomplia (Brand),"
"Acomplia (Generic)," "Rimonabant," "Herbal Ambien," and "Herbal Xanax" without approved
applications violates these provisions of the Act.
Your websites offer numerous products, including but not limited to "Valium (Brand)," "Valium
(Generic)," and "Prozac (Generic)," for sale without requiring that the products be dispensed
under a prescription from a duly licensed practitioner. Some of the products available on your
website are also controlled substances; the sale of these products is particularly concerning
because of the potential for abuse and dependency. Therefore, the drugs are misbranded under
section 503(b)(1) of the Act, 21 U.S.C. § 353(b)(1), and are marketed in violation of sections
301 (a), 301 (b), and 301 (k) of such Act, 21 U.S.C. §§ 331 (a), 331 (b), and 331 (k).
Further, your websites offer products for sale and state that they are FDA-approved. As noted
above, your products are not FDA-approved and are offered for sale in violation of the Act.
Therefore, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a),
because the labeling of the drugs is false and misleading.
In addition, you offer "Herbal Ambien" and "Herbal Xanax" for sale. These drugs are misbranded
under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false and
misleading. The labeling is false and misleading because it erroneously suggest that the
products contain Ambien or Xanax, which are the proprietary names for FDA-approved products
containing the active pharmaceutical ingredient zolpidem and alprazolam. Regardless of whether
your products contain Ambien or Xanax, the products you are offering for sale are not
manufactured by the sponsors of the approved applications for Ambien and Xanax, and it is false
and misleading to suggest that your products are manufactured by those sponsors.
The introduction or delivery for introduction into interstate commerce of these misbranded
products violates section 301 (a) of the Act, 21 U.S.C. § 331 (a).
This letter is not intended to identify all of the ways in which your activities might be in violation of United States law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.
Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries concerning this letter to FDA's Internet Pharmacy Task Force at FDAlnternetPharmacyTaskForceCDER@fda.hhs.gov or (301) 796-3110.
Deborah M. Autor, Esq.
Office of Compliance
Center for Drug Evaluation and Research